Transdermal Delivery of Pramipexole Using Microneedle Technology for the Potential Treatment of Parkinson’s Disease
Molecular Pharmaceutics · 06.05.2024 · 21 (5) · 2512-2533
DOI: 10.1021/acs.molpharmaceut.4c00065 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 11.04.2024. Verfasst von Mary B McGuckin und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, United Kingdom. Hauptthemen laut MEDLINE: Pramipexole, Parkinson Disease, Rats, Sprague-Dawley, Administration, Cutaneous. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department for the Economy.
Abstract (Originalsprache)
Parkinson's disease (PD) is a debilitating neurodegenerative disease primarily impacting neurons responsible for dopamine production within the brain. Pramipexole (PRA) is a dopamine agonist that is currently available in tablet form. However, individuals with PD commonly encounter difficulties with swallowing and gastrointestinal motility, making oral formulations less preferable. Microneedle (MN) patches represent innovative transdermal drug delivery devices capable of enhancing skin permeability through the creation of microconduits on the surface of the skin. MNs effectively reduce the barrier function of skin and facilitate the permeation of drugs. The work described here focuses on the development of polymeric MN systems designed to enhance the transdermal delivery of PRA. PRA was formulated into both dissolving MNs (DMNs) and directly compressed tablets (DCTs) to be used in conjunction with hydrogel-forming MNs (HFMNs). In vivo investigations using a Sprague-Dawley rat model examined, for the first time, if it was beneficial to prolong the application of DMNs and HFMNs beyond 24 h. Half of the patches in the MN cohorts were left in place for 24 h, whereas the other half remained in place for 5 days. Throughout the entire 5 day study, PRA plasma levels were monitored for all cohorts. This study confirmed the successful delivery of PRA from DMNs (Cmax = 511.00 ± 277.24 ng/mL, Tmax = 4 h) and HFMNs (Cmax = 328.30 ± 98.04 ng/mL, Tmax = 24 h). Notably, both types of MNs achieved sustained PRA plasma levels over a 5 day period. In contrast, following oral administration, PRA remained detectable in plasma for only 48 h, achieving a Cmax of 159.32 ± 113.43 ng/mL at 2 h. The HFMN that remained in place for 5 days demonstrated the most promising performance among all investigated formulations. Although in the early stages of development, the findings reported here offer a hopeful alternative to orally administered PRA. The sustained plasma profile observed here has the potential to reduce the frequency of PRA administration, potentially enhancing patient compliance and ultimately improving their quality of life. This work provides substantial evidence advocating the development of polymeric MN-mediated drug delivery systems to include sustained plasma levels of hydrophilic pharmaceuticals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, United Kingdom.
- Institute for Global Food Security, School of Biological Sciences, Queen's University Belfast, 19 Chlorine Gardens, Belfast BT9 5DL, United Kingdom.
- The International Joint Research Centre on Food Security (IJC-FOODSEC), 113 Thailand Science Park, Pahonyothin Road, Khong Luang ,Pathum Thani12120, Thailand.
ORCID-Profile: Helen O McCarthy, Alejandro J Paredes, Eneko Larrañeta, Ryan F Donnelly
Förderung
- Department for the Economy
Zitieren
APA
McGuckin, M. B., Hutton, A. R. J., Davis, E. R., Sabri, A. H. B., Ripolin, A., Himawan, A., Naser, Y. A., Ghanma, R., Greer, B., McCarthy, H. O., Paredes, A. J., Larrañeta, E., & Donnelly, R. F. (2024). Transdermal Delivery of Pramipexole Using Microneedle Technology for the Potential Treatment of Parkinson’s Disease. Molecular Pharmaceutics, 21(5), 2512-2533. https://doi.org/10.1021/acs.molpharmaceut.4c00065
Vancouver
McGuckin MB, Hutton ARJ, Davis ER, Sabri AHB, Ripolin A, Himawan A, et al. Transdermal Delivery of Pramipexole Using Microneedle Technology for the Potential Treatment of Parkinson’s Disease. Molecular Pharmaceutics. 2024;21(5):2512-2533. doi:10.1021/acs.molpharmaceut.4c00065
BibTeX
@article{McGuckin2024,
author = {McGuckin, Mary B and Hutton, Aaron R J and Davis, Ellie R and Sabri, Akmal H B and Ripolin, Anastasia and Himawan, Achmad and Naser, Yara A and Ghanma, Rand and Greer, Brett and McCarthy, Helen O and Paredes, Alejandro J and Larrañeta, Eneko and Donnelly, Ryan F},
title = {Transdermal Delivery of Pramipexole Using Microneedle Technology for the Potential Treatment of Parkinson’s Disease},
journal = {Molecular Pharmaceutics},
year = {2024},
volume = {21},
number = {5},
pages = {2512--2533},
doi = {10.1021/acs.molpharmaceut.4c00065}
}
EUVIMED